Sysmex Inostics
Jonathan Craft has a diverse work experience in the field of translational research and product design. Jonathan currently serves as the Associate Director of Translational Research and Product Design at Sysmex Inostics, a role they have held since April 2022. Prior to this position, they worked as a Senior Manager of Translational Research and Product Design at the same company from September 2021 to April 2022. Before joining Sysmex Inostics, Jonathan worked as a Product Development Manager and Translational Expert at Sysmex Inostics from May 2020 to September 2021. Prior to their work at Sysmex Inostics, Jonathan gained research experience at Myriad Genetics as a Research Associate II-III from July 2011 to May 2020, where they contributed to the design, development, and validation of various clinical diagnostic tests. Jonathan also supported different departments within the company. Jonathan's earlier experience includes working as a Graduate Student at the University of Utah from July 2006 to June 2011, where they were involved in projects related to microtubules and mRNA regulation.
Jonathan Craft attended West Virginia University Institute of Technology from 2002 to 2006. Jonathan earned a Bachelor of Science degree in Biology during this time.
This person is not in any teams
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.